- Home
- HG vs AAPG Comparison
HG vs AAPG Comparison
Compare HG & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HG
- AAPG
- Stock Information
- Founded
- HG 2013
- AAPG 2009
- Country
- HG Bermuda
- AAPG China
- Employees
- HG N/A
- AAPG 567
- Industry
- HG
- AAPG Biotechnology: Pharmaceutical Preparations
- Sector
- HG
- AAPG Health Care
- Exchange
- HG Nasdaq
- AAPG Nasdaq
- Market Cap
- HG 2.0B
- AAPG 2.2B
- IPO Year
- HG 2023
- AAPG 2025
- Fundamental
- Price
- HG $21.74
- AAPG $24.40
- Analyst Decision
- HG Buy
- AAPG Buy
- Analyst Count
- HG 5
- AAPG 1
- Target Price
- HG $23.80
- AAPG N/A
- AVG Volume (30 Days)
- HG 502.5K
- AAPG 14.1K
- Earning Date
- HG 05-07-2025
- AAPG 06-10-2025
- Dividend Yield
- HG N/A
- AAPG N/A
- EPS Growth
- HG N/A
- AAPG N/A
- EPS
- HG 3.03
- AAPG N/A
- Revenue
- HG $2,443,695,000.00
- AAPG $134,352,180.00
- Revenue This Year
- HG $14.65
- AAPG N/A
- Revenue Next Year
- HG $16.71
- AAPG $389.09
- P/E Ratio
- HG $7.18
- AAPG N/A
- Revenue Growth
- HG 27.70
- AAPG 341.77
- 52 Week Low
- HG $15.19
- AAPG $16.50
- 52 Week High
- HG $21.92
- AAPG $26.55
- Technical
- Relative Strength Index (RSI)
- HG 68.37
- AAPG N/A
- Support Level
- HG $20.68
- AAPG N/A
- Resistance Level
- HG $21.42
- AAPG N/A
- Average True Range (ATR)
- HG 0.46
- AAPG 0.00
- MACD
- HG 0.08
- AAPG 0.00
- Stochastic Oscillator
- HG 90.23
- AAPG 0.00
About HG Hamilton Insurance Group Ltd. Class B
Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.
About AAPG Ascentage Pharma Group International American Depository Shares
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.